|
Status |
Public on Jan 31, 2021 |
Title |
GTG_140_55: NCI-H1299 |
Sample type |
SRA |
|
|
Source name |
NCI-H1299
|
Organism |
Homo sapiens |
Characteristics |
cell line: NCI-H1299 disease: non-small cell lung carcinoma treatment: DMSO dose: .
|
Treatment protocol |
Cells were treated with DMSO or indicated inhibitors for 24 hr
|
Growth protocol |
Cell Lines were cultured in RPMI-1640 + 10% FBS
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was prepared by Qiazol extraction followed by RNeasy mini column (QIAGEN) 10 ug of total RNA was submitted to poly-A selection to remove ribosomal RNA and reverse transcribed to double-stranded cDNA. The cDNA was eblunt ended, adenylated, and ligated with Illumina indexes.
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina HiSeq 3000 |
|
|
Data processing |
Illumina Casava1.8 software used for basecalling Reads were aligned using the OmicSoft aligner and gene expression quantified based on UCSC gene model. Differentially expressed genes between treatment conditions detected by DESeq2 with a statistical cut-off (FC>2, p<0.01) Genome_build: B37
|
|
|
Submission date |
Jan 27, 2020 |
Last update date |
Jan 31, 2021 |
Contact name |
Xin Lu |
E-mail(s) |
xin.x.lu@abbvie.com
|
Phone |
847-937-7942
|
Organization name |
Abbvie
|
Department |
Oncology Discovery
|
Street address |
1 North Waukegan Rd
|
City |
North Chicago |
State/province |
IL |
ZIP/Postal code |
60064 |
Country |
USA |
|
|
Platform ID |
GPL21290 |
Series (1) |
GSE144326 |
Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia |
|
Relations |
BioSample |
SAMN13930158 |
SRA |
SRX7637651 |